Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 427

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Soluble Urokinase Receptor and Chronic Kidney Disease

Open access
Hayek, Salim S., Sever, Sanja, Ko, Yi-An, Trachtman, Howard, Awad, Mosaab, Wadhwani, Shikha, Altintas, Mehmet M., Wei, Changli, Hotton, Anna L., French, Audrey L., Sperling, Laurence S., Lerakis, Stamatios, Quyyumi, Arshed A., Reiser, Jochen·2015·New England Journal of Medicine

Abstract

BACKGROUND: Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions. It is unknown whether elevated suPAR levels in patients with normal kidney function are associated with future decline in the estimated glomerular filtration rate (eGFR) and with incident chronic kidney disease. METHODS: We measured plasma suPAR levels in 3683 persons enrolled in the Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median suPAR level, 3040 pg per milliliter) and determined renal function at enrollment and at subsequent visits in 2292 persons. The relationship between suPAR levels and the eGFR at baseline, the change in the eGFR over time, and the development of chronic kidney disease (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear mixed models and Cox regression after adjustment for demographic and clinical variables. RESULTS: A higher suPAR level at baseline was associated with a greater decline in the eGFR during follow-up; the annual change in the eGFR was -0.9 ml per minute per 1.73 m(2) among participants in the lowest quartile of suPAR levels as compared with -4.2 ml per minute per 1.73 m(2) among participants in the highest quartile (P<0.001). The 921 participants with a normal eGFR (≥ 90 ml per minute per 1.73 m(2)) at baseline had the largest suPAR-related decline in the eGFR. In 1335 participants with a baseline eGFR of at least 60 ml per minute per 1.73 m(2), the risk of progression to chronic kidney disease in the highest quartile of suPAR levels was 3.13 times as high (95% confidence interval, 2.11 to 4.65) as that in the lowest quartile. CONCLUSIONS: An elevated level of suPAR was independently associated with incident chronic kidney disease and an accelerated decline in the eGFR in the groups studied. (Funded by the Abraham J. and Phyllis Katz Foundation and others.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1506362

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 427

Metadata

Authors
Hayek, S. S., Sever, S., Ko, Y.-A., Trachtman, H., Awad, M., Wadhwani, S., Altintas, M. M., Wei, C., Hotton, A. L., French, A. L., Sperling, L. S., Lerakis, S., Quyyumi, A. A., & Reiser, J.
Venue
New England Journal of Medicine
Published
2015-11-12
Volume
373
Issue
20
Pages
1916-1925
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2195506720
Cited by
427
References
39
FWCI
29.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Soluble Urokinase Receptor and Chronic Kidney Disease. https://app.cochat.ai/papers/10.1056/nejmoa1506362
The paper
Hayek, S. S., Sever, S., Ko, Y.-A., Trachtman, H., Awad, M., Wadhwani, S., Altintas, M. M., Wei, C., Hotton, A. L., French, A. L., Sperling, L. S., Lerakis, S., Quyyumi, A. A., & Reiser, J. (2015). Soluble Urokinase Receptor and Chronic Kidney Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1506362

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.